{"title":"The Link between Arterial Atherosclerotic and Venous Thromboembolic Disease.","authors":"Pavel Poredos, Peter Poredos, Mateja K Jezovnik","doi":"10.2174/0115701611345232250212042958","DOIUrl":null,"url":null,"abstract":"<p><p>Traditionally, arterial atherosclerotic (AA) and venous thromboembolic (VTE) diseases have been separated into two independent entities. However, a body of evidence suggests the link between arterial and venous disease. In this narrative review, the relationship between these two vascular diseases is discussed. Different risk factors are common in both diseases, such as dyslipidaemia, metabolic syndrome, and thrombophilia. Etiopathogenetic mechanisms of both diseases are similar. Inflammation, as a basic pathogenetic mechanism of atherosclerotic disease, is also involved in the pathogenesis of VTE. Inflammation as a response to vessel wall injury promotes coagulation and inhibits endogenic fibrinolytic activity, which results in thromboembolic events in the arterial as well as in the venous system. A relationship has also been observed between preclinical or clinical atherosclerotic disease and VTE. These findings indicate that atherosclerosis may induce VTE or that common risk factors simultaneously stimulate the development of both diseases. The relationship between arterial and venous disease is also supported by the efficacy of some drugs (antiplatelets, anticoagulants, statins) in the prevention of both diseases. In conclusion, arterial and venous diseases share similar pathophysiological mechanisms, often driven by common risk factors. This overlap suggests that a unified approach to prevention and treatment may be beneficial for both conditions, potentially improving patient outcomes by addressing the underlying shared pathways.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current vascular pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115701611345232250212042958","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Traditionally, arterial atherosclerotic (AA) and venous thromboembolic (VTE) diseases have been separated into two independent entities. However, a body of evidence suggests the link between arterial and venous disease. In this narrative review, the relationship between these two vascular diseases is discussed. Different risk factors are common in both diseases, such as dyslipidaemia, metabolic syndrome, and thrombophilia. Etiopathogenetic mechanisms of both diseases are similar. Inflammation, as a basic pathogenetic mechanism of atherosclerotic disease, is also involved in the pathogenesis of VTE. Inflammation as a response to vessel wall injury promotes coagulation and inhibits endogenic fibrinolytic activity, which results in thromboembolic events in the arterial as well as in the venous system. A relationship has also been observed between preclinical or clinical atherosclerotic disease and VTE. These findings indicate that atherosclerosis may induce VTE or that common risk factors simultaneously stimulate the development of both diseases. The relationship between arterial and venous disease is also supported by the efficacy of some drugs (antiplatelets, anticoagulants, statins) in the prevention of both diseases. In conclusion, arterial and venous diseases share similar pathophysiological mechanisms, often driven by common risk factors. This overlap suggests that a unified approach to prevention and treatment may be beneficial for both conditions, potentially improving patient outcomes by addressing the underlying shared pathways.
期刊介绍:
Current Vascular Pharmacology publishes clinical and research-based reviews/mini-reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research.
Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).